ArticleThe American journal of surgical pathology2011
Fallopian tube correlates of ovarian serous borderline tumors.
Article in The American journal of surgical pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 65 citations in OpenAlex.
- Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population-based case-control study in Sweden.International journal of cancer · 2025Article
- Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression.Cells · 2022Article
- Pathologic Classification of Ovarian Cancer.Methods in molecular biology (Clifton, N.J.) · 2022Article
- STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?The journal of pathology. Clinical research · 2021Article
- Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study.Journal of oncology · 2019Article
- Article
- A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.Seminars in diagnostic pathology · 2018Review
- Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.Virchows Archiv : an international journal of pathology · 2017Review
- Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.JCI insight · 2016Article
- Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.The American journal of surgical pathology · 2015Article
- Incidence of serous tubal intraepithelial carcinoma (STIC) by algorithm classification in serous ovarian tumor associated with PAX8 expression in tubal epithelia: a study of single institution in Japan.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2015Article
- The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium.The Journal of pathology · 2014Article
- Early preinvasive lesions in ovarian cancer.BioMed research international · 2014Review
- Tubal origin of ovarian low-grade serous carcinoma.American journal of clinical and experimental obstetrics and gynecology · 2013Article
- Coming into focus: the nonovarian origins of ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Review
- Article
- Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms.Frontiers in oncology · 2013Article
- Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis.Journal of hematology & oncology · 2012Review
- Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.Virchows Archiv : an international journal of pathology · 2012Review
- The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".Clinical obstetrics and gynecology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Ovarian serous borderline tumors (SBTs) are presumed to originate in the ovarian cortex or peritoneal surface. The pathogenetic role of the fallopian tube (FT) is unclear; however, recently, secretory cell outgrowths (SCOUTs) lacking PAX2 expression were described in benign FTs. This study addressed (1) the differentiation characteristics of SBTs and (2) the frequency of SCOUTs lacking PAX2 expression in the FTs of patients with SBTs and compared (3) SCOUT morphology and (4) PAX2 expression with SBTs. SBTs and FT epithelium shared both ciliated (p73) and secretory (HMFG2) differentiation. PAX2-null SCOUT frequency in FT cross-sections from patients with SBTs was 0.28 (110 of 398) versus 0.112 in benign hysterectomies and nearly 0 in pediatric and postpartum sterilization specimens (P = < 0.001). When adjusted for age, the differences narrowed but remained significant (P = 0.010). SCOUTs were heterogeneous, some displaying ciliated differentiation and papillary architecture. Two cases of discrete multifocal papillary SCOUTs in the FTs were associated with SBTs. All SBTs had heterogeneous PAX2 staining with areas of PAX2 loss. This study shows for the first time that PAX2-null SCOUTs are more common in the oviducts of women with SBTs and that loss of PAX2 expression occurs in most SBTs. These discoveries link both morphologic and functional gene (PAX2) alterations in the oviduct to SBTs, similar to that reported in high-grade serous carcinoma. Further study is warranted to clarify the relationship of the oviduct to serous neoplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.